Cargando…
Attempt towards a novel classification of triple-negative breast cancer using immunohistochemical markers
Significant efforts have been made to gain a better understanding of the heterogeneity of triple-negative breast cancers from the histological to the molecular and genomic levels. In this study, we attempted to bring forward gene expression subtypes of triple-negative breast cancer (TBNC) to the cli...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4950427/ https://www.ncbi.nlm.nih.gov/pubmed/27446423 http://dx.doi.org/10.3892/ol.2016.4778 |
_version_ | 1782443560541356032 |
---|---|
author | Liu, Yan-Xi Wang, Ke-Ren Xing, Hua Zhai, Xu-Jie Wang, Li-Ping Wang, Wan |
author_facet | Liu, Yan-Xi Wang, Ke-Ren Xing, Hua Zhai, Xu-Jie Wang, Li-Ping Wang, Wan |
author_sort | Liu, Yan-Xi |
collection | PubMed |
description | Significant efforts have been made to gain a better understanding of the heterogeneity of triple-negative breast cancers from the histological to the molecular and genomic levels. In this study, we attempted to bring forward gene expression subtypes of triple-negative breast cancer (TBNC) to the clinic, by translating gene stratification to clinically accessible immunohistochemical (IHC) classification. Using IHC analysis, we categorized 154 TBNC cases into three main subclasses. Differences in the frequencies of basic characteristics and clinicopathological parameters between the subtypes were examined using Chi-square tests. We defined three main groups among the 154 triple-negative cases. The basal-like (BL) group expressed cytokeratin (CK) 5/6 and/or CK14 (83 cases), the AR(+) group demonstrated positivity for androgen receptor (18 cases), and the final group exhibited a CD44+CD24-(/)low phenotype (39 cases). There were three overlapping cases between the BL subgroup and the CD44+CD24-/low phenotype subgroup, and 11 unclassified cases. In this new IHC classification, three subcategories exhibited a statistical difference with regard to age, tumor size, histological grade, tumor necrosis, Ki67 labeling index, relapse-free survival, breast cancer-specific survival and response to chemotherapy. According to our definition, the BL group and CD44+CD24-(/)low phenotype could be observed in tumors that were not triple-negative, and BL tumors that were triple-negative demonstrated almost undistinguishable clinicopathological characteristics compared with BL tumors that were not triple-negative. The same observation was made with CD44+CD24-/low tumors that were triple-negative vs. CD44+CD24-(/)low tumors that were not. The AR+ group demonstrated undistinguishable clinicopathological characteristics compared with the luminal subtype. We successfully distinguished three subtypes exhibiting diverse clinicopathological and prognostic characteristics with the minimum use of IHC markers. |
format | Online Article Text |
id | pubmed-4950427 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-49504272016-07-21 Attempt towards a novel classification of triple-negative breast cancer using immunohistochemical markers Liu, Yan-Xi Wang, Ke-Ren Xing, Hua Zhai, Xu-Jie Wang, Li-Ping Wang, Wan Oncol Lett Articles Significant efforts have been made to gain a better understanding of the heterogeneity of triple-negative breast cancers from the histological to the molecular and genomic levels. In this study, we attempted to bring forward gene expression subtypes of triple-negative breast cancer (TBNC) to the clinic, by translating gene stratification to clinically accessible immunohistochemical (IHC) classification. Using IHC analysis, we categorized 154 TBNC cases into three main subclasses. Differences in the frequencies of basic characteristics and clinicopathological parameters between the subtypes were examined using Chi-square tests. We defined three main groups among the 154 triple-negative cases. The basal-like (BL) group expressed cytokeratin (CK) 5/6 and/or CK14 (83 cases), the AR(+) group demonstrated positivity for androgen receptor (18 cases), and the final group exhibited a CD44+CD24-(/)low phenotype (39 cases). There were three overlapping cases between the BL subgroup and the CD44+CD24-/low phenotype subgroup, and 11 unclassified cases. In this new IHC classification, three subcategories exhibited a statistical difference with regard to age, tumor size, histological grade, tumor necrosis, Ki67 labeling index, relapse-free survival, breast cancer-specific survival and response to chemotherapy. According to our definition, the BL group and CD44+CD24-(/)low phenotype could be observed in tumors that were not triple-negative, and BL tumors that were triple-negative demonstrated almost undistinguishable clinicopathological characteristics compared with BL tumors that were not triple-negative. The same observation was made with CD44+CD24-/low tumors that were triple-negative vs. CD44+CD24-(/)low tumors that were not. The AR+ group demonstrated undistinguishable clinicopathological characteristics compared with the luminal subtype. We successfully distinguished three subtypes exhibiting diverse clinicopathological and prognostic characteristics with the minimum use of IHC markers. D.A. Spandidos 2016-08 2016-06-23 /pmc/articles/PMC4950427/ /pubmed/27446423 http://dx.doi.org/10.3892/ol.2016.4778 Text en Copyright: © Liu et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Articles Liu, Yan-Xi Wang, Ke-Ren Xing, Hua Zhai, Xu-Jie Wang, Li-Ping Wang, Wan Attempt towards a novel classification of triple-negative breast cancer using immunohistochemical markers |
title | Attempt towards a novel classification of triple-negative breast cancer using immunohistochemical markers |
title_full | Attempt towards a novel classification of triple-negative breast cancer using immunohistochemical markers |
title_fullStr | Attempt towards a novel classification of triple-negative breast cancer using immunohistochemical markers |
title_full_unstemmed | Attempt towards a novel classification of triple-negative breast cancer using immunohistochemical markers |
title_short | Attempt towards a novel classification of triple-negative breast cancer using immunohistochemical markers |
title_sort | attempt towards a novel classification of triple-negative breast cancer using immunohistochemical markers |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4950427/ https://www.ncbi.nlm.nih.gov/pubmed/27446423 http://dx.doi.org/10.3892/ol.2016.4778 |
work_keys_str_mv | AT liuyanxi attempttowardsanovelclassificationoftriplenegativebreastcancerusingimmunohistochemicalmarkers AT wangkeren attempttowardsanovelclassificationoftriplenegativebreastcancerusingimmunohistochemicalmarkers AT xinghua attempttowardsanovelclassificationoftriplenegativebreastcancerusingimmunohistochemicalmarkers AT zhaixujie attempttowardsanovelclassificationoftriplenegativebreastcancerusingimmunohistochemicalmarkers AT wangliping attempttowardsanovelclassificationoftriplenegativebreastcancerusingimmunohistochemicalmarkers AT wangwan attempttowardsanovelclassificationoftriplenegativebreastcancerusingimmunohistochemicalmarkers |